Foghorn Therapeutics Inc. (FHTX)

Foghorn Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	80.88	55.45	80.34	52.21	101.14
Short-Term Investments	78.02	188.29	153.72	293.58	53.15
Cash & Short-Term Investments	158.89	243.75	234.06	345.8	154.29
Cash Growth	-34.81%	4.14%	-32.31%	124.12%	-16.95%
Other Current Assets	4.34	5.85	6.12	5.6	5.27
Total Current Assets	163.24	249.6	240.18	351.4	459.56
Net Property, Plant & Equipment	32.86	32.61	42.91	49.4	56.08
Other Long-Term Assets	2	1.78	2.82	4.09	4.13
Total Assets	198.1	283.98	285.92	404.88	519.77
Accounts Payable	4.27	3.79	6.26	5.41	3.82
Accrued Expenses	11.36	8.53	9.11	11	9.56
Current Portion of Leases	0.92	9.07	8.52	5.97	6.99
Unearned Revenue	43.19	45.61	34.55	32.82	28.32
Total Current Liabilities	59.74	66.99	58.44	55.21	48.69
Long-Term Leases	40.35	28.06	36.56	45.54	51.34
Other Long-Term Liabilities	206.52	234.46	268.12	304.03	322.87
Total Long-Term Liabilities	246.87	262.52	304.67	349.57	374.21
Total Liabilities	306.6	329.51	363.11	404.77	422.9
Common Stock	0.01	0.01	0	0	0
Additional Paid-in Capital	523.94	512.52	395.2	377.23	361.13
Accumulated Other Comprehensive Income	0.02	0.14	-0.83	-3.99	-0.01
Retained Earnings	-632.47	-558.18	-471.56	-373.14	-264.26
Shareholders' Equity	-108.5	-45.53	-77.19	0.11	96.87
Total Liabilities & Equity	198.1	283.98	285.92	404.88	519.77
Total Debt	41.27	37.13	45.07	51.51	58.33
Net Cash (Debt)	117.62	206.62	188.98	294.29	95.96
Net Cash Growth	-43.07%	9.33%	-35.78%	206.69%	-7.53%
Net Cash Per Share	1.87	3.76	4.50	7.08	2.58
Book Value	-108.5	-45.53	-77.19	0.11	96.87
Book Value Per Share	-1.72	-0.83	-1.84	0.00	2.61
Tangible Book Value	-108.5	-45.53	-77.19	0.11	96.87
Tangible Book Value Per Share	-1.72	-0.83	-1.84	0.00	2.61

Updated Mar 11, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q